Abbott Laboratories (ABT) : Northwest Investment Counselors scooped up 6,517 additional shares in Abbott Laboratories during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 21, 2016. The investment management firm now holds a total of 17,710 shares of Abbott Laboratories which is valued at $780,657.Abbott Laboratories makes up approximately 0.44% of Northwest Investment Counselors’s portfolio.
Abbott Laboratories closed down -0.05 points or -0.11% at $43.83 with 50,35,092 shares getting traded on Wednesday. Post opening the session at $43.93, the shares hit an intraday low of $43.69 and an intraday high of $44 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
Other Hedge Funds, Including , Nichols Asset Management reduced its stake in ABT by selling 1,000 shares or 9.07% in the most recent quarter. The Hedge Fund company now holds 10,020 shares of ABT which is valued at $441,682. Abbott Laboratories makes up approx 0.10% of Nichols Asset Management’s portfolio.Aull Monroe Investment Management Corp reduced its stake in ABT by selling 1,100 shares or 3.28% in the most recent quarter. The Hedge Fund company now holds 32,447 shares of ABT which is valued at $1,430,264. Abbott Laboratories makes up approx 0.84% of Aull Monroe Investment Management Corp’s portfolio.Osborn Rohs Williams Donohoe Ltd boosted its stake in ABT in the latest quarter, The investment management firm added 3,553 additional shares and now holds a total of 139,752 shares of Abbott Laboratories which is valued at $6,066,634. Abbott Laboratories makes up approx 1.20% of Osborn Rohs Williams Donohoe Ltd’s portfolio.Abner Herrman Brock boosted its stake in ABT in the latest quarter, The investment management firm added 30,737 additional shares and now holds a total of 153,187 shares of Abbott Laboratories which is valued at $6,507,384. Abbott Laboratories makes up approx 1.65% of Abner Herrman Brock’s portfolio.
On the company’s financial health, Abbott Laboratories reported $0.41 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Apr 20, 2016. Analyst had a consensus of $0.39. The company had revenue of $4885.00 million for the quarter, compared to analysts expectations of $4777.68 million. The company’s revenue was down -.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.47 EPS.
Many Wall Street Analysts have commented on Abbott Laboratories. Company shares were Reiterated by RBC Capital Mkts on Apr 11, 2016 to “Outperform”, Firm has raised the Price Target to $ 48 from a previous price target of $45 .Shares were Reiterated by RBC Capital Mkts on Jan 29, 2016 to “Outperform” and Lowered the Price Target to $ 45 from a previous price target of $51 .
Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.